Anavex Announces Two-Year Clinical Extension Study of ANAVEX 2-73 and Presents Phase 2a Dose-Response Analysis at AAT Conference

Trial Extension Granted at Request of Patients and Caregivers NEW YORK, NY – March 10, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced that the Company has received the approval from the Ethics Committee in Australia to extend the ongoing Phase 2a Alzheimer’s trial, which had been requested by…

Anavex Presents Preclinical Results of ANAVEX 2-73 in Rett Syndrome

– Data presentation at 2016 Epilepsy Pipeline Conference – – Company exploring potential to advance ANAVEX 2-73 into human clinical studies in rare disease indication – NEW YORK, NY – February 25, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of…

ANAVEX 2-73 Preclinical Data in New Indication to be Presented at ACTRIMS 2016

– Preclinical data relevant for multiple sclerosis and other neurodegenerative diseases – NEW YORK, NY – February 17, 2016 – Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various…

Anavex Reports Fiscal First Quarter 2016 Financial Results

New York, NY – February 8, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three months ended…

Anavex to Present at 18th Annual BIO CEO & Investor Conference on February 9th 2016

New York — February 2, 2016 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive…